We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NMAX:NYSENewsmax, Inc. Analysis

Data as of 2026-06-30 - not real-time

$7.78

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Newsmax, Inc. is trading just below its short‑term moving average while remaining under its longer‑term trend line, suggesting limited upside in the immediate window. The 14‑day RSI sits near the midpoint, indicating no clear overbought or oversold condition. Technical momentum is bearish as the MACD line trails its signal, reinforcing a neutral to slightly negative short‑term bias. The stock exhibits elevated volatility and a beta well above the market, pointing to heightened price swings. Fundamentally, the forward price‑to‑earnings multiple is dramatically higher than the industry average, and the price‑to‑book ratio is also stretched, implying the market is pricing in strong growth expectations. Recent corporate communication highlights an unexpected surge in international licensing revenue, with projections far exceeding prior guidance, which could serve as a catalyst for future earnings improvement.
Despite the growth narrative, the company continues to generate negative operating cash flow and carries a high debt‑to‑equity ratio relative to its cash position, raising concerns about sustainability. Profit margins remain deeply negative, and return metrics are in the red, underscoring significant execution risk. The analyst consensus leans heavily toward a strong‑buy stance, reflecting optimism about the international expansion and potential turnaround. However, the combination of lofty valuation multiples, high volatility, and weak profitability suggests that investors should be cautious and weigh the upside against the substantial downside risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD momentum
  • Neutral RSI indicating no clear entry point
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • International licensing revenue acceleration
  • Analyst strong‑buy consensus
  • Potential improvement in cash flow from new markets

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Growth‑oriented valuation outlook
  • Strategic expansion beyond domestic market
  • Long‑term upside if profitability metrics turn positive

Key Metrics & Analysis

Financial Health

Revenue Growth14.00%
Profit Margin-43.17%
P/E Ratio111.1
ROE-59.39%
ROA-22.98%
Debt/Equity7.78
P/B Ratio9.4
Op. Cash Flow$-91371760
Free Cash Flow$-60526588
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI50.9
Support$6.52
Resistance$10.00
MA 20$8.15
MA 50$7.41
MA 200$8.20
MACDBearish
VolumeStable
Fear & Greed Index89.91

Valuation

Target Price$18.50
Upside/Downside137.79%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.66
Volatility84.95%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.